Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases

NCT01888484 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT01888484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01888484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2014
Completion date
June 9, 2020
Enrollment
75 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency disorder